 Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 3 | 3 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 7 | 7 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 3 | 3 | | 2005 | 0 | 8 | 8 | | 2006 | 0 | 8 | 8 | | 2007 | 0 | 9 | 9 | | 2008 | 0 | 9 | 9 | | 2009 | 0 | 22 | 22 | | 2010 | 1 | 29 | 30 | | 2011 | 7 | 13 | 20 | | 2012 | 11 | 6 | 17 | | 2013 | 20 | 9 | 29 | | 2014 | 10 | 13 | 23 | | 2015 | 6 | 9 | 15 | | 2016 | 8 | 6 | 14 | | 2017 | 13 | 12 | 25 | | 2018 | 7 | 16 | 23 | | 2019 | 29 | 16 | 45 | | 2020 | 31 | 22 | 53 | | 2021 | 21 | 38 | 59 | | 2022 | 10 | 42 | 52 | | 2023 | 5 | 45 | 50 | | 2024 | 47 | 12 | 59 | | 2025 | 41 | 14 | 55 | | 2026 | 10 | 6 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Pingeon O, Grellier N, Coulm B, Beghin D, Chambers C, Chasset F, Fautrel B, Julsgaard M, Restellini S, Dechartres A, Kirchgesner J, Marin B. Safety of advanced therapies during pregnancy in women with immune-mediated inflammatory diseases: a systematic review and meta-analysis. J Crohns Colitis. 2026 May 08; 20(5).
-
Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunol Immunother. 2026 Mar 24; 75(4).
-
Dai Y, Brouillard J, Jaycox JR, Yeon SM, Huck JD, Yandamuri SS, Zhong Z, O'Connor KC, Burnina I, Henkel C, LeMay AK, Lilov A, McGurk E, Morrill M, Parker L, Sackett T, Sandberg C, Sivasubramanian A, Geoghegan JC, Ring AM. Off-target reactivity in clinical monoclonal antibodies. Structure. 2026 May 07; 34(5):747-757.e5.
-
Zoref-Lorenz A, Allen CE, Behrens EM, Chandrakasan S, Chien M, Hermiston ML, Hinson AP, Intzes S, Isakoff MS, Leiding JW, Oladapo A, Panigrahi A, Patel SA, Pednekar P, Ray AK, Rothman JA, Saldaña BD, Walkovich KJ, Weinstein J, Yee JD, Jordan MB, Weinstein J, Hinson AP, Allen CE, Eckstein OS, Gulati N, Chandrakasan S, Haines H, Nakano TA, Patel SA, Behrens EM, Intzes S, Hays A, Saldaña BD, Jordan MB, Zoref-Lorenz A, Hanna R, Isakoff M, Ray AK, Rothman JA, Tandra A, Cooper R, Leiding JW, Chien M, Sarangi S, Gidvani-Diaz VK, Satwani P, Carter J, Henry M, Gloude N, Bhatt S, Bhatla D, Draper L, Panigrahi A, Hermiston ML, Modica R, Riskalla M, Baker A, Ward B. Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.
-
Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, Bajor DL, Mukherjee S, Saltzman J, Maguire O, Minderman H, Chatley S, Tarquini ML, Whitworth A, Jurcevic J, Hsiao HH, Knudsen ES, Muhitch JB, Abrams SI, Kalinski P, Segal BH, Bakin A, Yuan G, Wang C, Attwood K, Iyer R, Boland PM. TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. Int J Cancer. 2026 Jun 15; 158(12):3300-3311.
-
Sessions J, Bauer M, Menard-Katcher C, Nguyen N. Advances in Management of Eosinophilic Esophagitis in Pediatrics. Paediatr Drugs. 2026 May; 28(3):269-283.
-
Cerbone L, Roviello G, Calabrò F, Taha T, Grande E, Binz K, Kanesvaran R, Pirstuk A, Fiala O, Molina-Cerrillo J, Alonso-Gordoa T, Rizzo A, Pichler R, Myint ZW, Poprach A, Facchini G, Bohuslav M, Studentova H, Morelli F, Buchler T, Mennitto A, Tural D, Formisano L, Orejana I, Catalano M, Buti S, Monteiro FSM, Soares A, Gupta S, Massari F, Santoni M. Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? Front Immunol. 2026; 17:1667155.
-
Rommer PS, Jiang W, Nolte JP, Mikami T, De Seze J, Sánchez P, Harel A, Alkabie S, Kaneko K, Bilodeau PA, Misu T, Kremer L, Bigaut K, Leypoldt F, Aktas O, Ringelstein M, Siffrin V, Zhang LJ, Cong H, Lowe M, Barreras P, Chen H, Piquet AL, Sotirchos ES, Kammeyer R, Zook J, Bennett JL, Berger T, Fujihara K, Levy M, Shi FD, Paul F. Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series. Neurol Neuroimmunol Neuroinflamm. 2026 Mar; 13(2):e200548.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|